Compare
Abpro Holdings, Inc. vs Zeo ScientifiX, Inc. vs BioCardia, Inc. vs VivoSim Labs, Inc.
| Latest fiscal year | Abpro Holdings, Inc. ABPO | Zeo ScientifiX, Inc. ZEOX | BioCardia, Inc. BCDA | VivoSim Labs, Inc. VIVS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-10-31 | 2025-12-31 | 2026-03-31 |
| Revenue | n/a | $5.20M | $0 | $131.0K |
| Revenue growth (YoY) | n/a | +12.5% | -100.0% | -9.0% |
| Gross margin | n/a | 82.1% | n/a | n/a |
| Operating margin | n/a | -103.6% | n/a | n/m |
| Net margin | n/a | -106.2% | n/a | n/m |
| Net income | -$2.89M | -$5.52M | -$8.23M | -$13.84M |
| EPS (Diluted) | -$1.30 | -$0.86 | n/a | -$5.35 |
| Operating cash flow | -$6.01M | -$718.0K | -$7.44M | -$10.83M |
| Free cash flow | n/a | -$741.0K | -$7.44M | -$10.83M |
| Cash & equivalents | n/a | n/a | $2.50M | $5.02M |
| Total assets | $1.06M | $1.53M | $3.41M | $7.39M |
| Total liabilities | n/a | $2.95M | $2.52M | $8.48M |
| Shareholders' equity | -$8.83M | -$1.42M | $895.0K | -$1.10M |
| Return on year-end equity | n/a | n/a | -919.3% | n/a |
| Shares outstanding | 2.73M | 6.75M | 10.76M | 2.89M |
Revenue, most recent five fiscal years
| Fiscal year | Abpro Holdings, Inc. | Zeo ScientifiX, Inc. | BioCardia, Inc. | VivoSim Labs, Inc. |
|---|---|---|---|---|
| Latest | $183.0K Ended 2024-12-31 | $5.20M Ended 2025-10-31 | $0 Ended 2025-12-31 | $131.0K Ended 2026-03-31 |
| 1 year earlier | $122.0K Ended 2023-12-31 | $4.62M Ended 2024-10-31 | $58.0K Ended 2024-12-31 | $144.0K Ended 2025-03-31 |
| 2 years earlier | n/a | $4.56M Ended 2023-10-31 | $477.0K Ended 2023-12-31 | $109.0K Ended 2024-03-31 |
| 3 years earlier | n/a | $6.49M Ended 2022-10-31 | $1.35M Ended 2022-12-31 | $370.0K Ended 2023-03-31 |
| 4 years earlier | n/a | $5.60M Ended 2021-10-31 | $1.01M Ended 2021-12-31 | $1.50M Ended 2022-03-31 |